Wendy Stock
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 295
- Acute Myeloid Leukemia Research 201
- Chronic Myeloid Leukemia Treatments 104
- Hematopoietic Stem Cell Transplantation 62
-
- Acute Lymphoblastic Leukemia research 222
- Co-authors
- Richard A. Larson (145 shared papers)Daniel DeAngelo (42 shared papers)Hagop Kantarjian (34 shared papers)Koen van Besien (70 shared papers)Anjali S. Advani (30 shared papers)Andrew S. Artz (76 shared papers)Erik R. Vandendries (21 shared papers)Matthias Stelljes (19 shared papers)
- Journals
- Blood (142 papers)Blood Advances (43 papers)Transplantation and Cellular Therapy (28 papers)Bone Marrow Transplantation (16 papers)Journal of Clinical Oncology (15 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Wendy Stock
482 papers receiving 22.1k citations
Wendy Stock's Hit Papers
Peers
Comparison fields: 5 of 146
- Hematology 11.4k
- Genetics 3.9k
- Public Health, Environmental and Occupational Health 8.3k
- Oncology 4.8k
- Pediatrics, Perinatology and Child Health 3.1k
Countries citing papers authored by Wendy Stock
This map shows the geographic impact of Wendy Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Stock more than expected).
Fields of papers citing papers by Wendy Stock
This network shows the impact of papers produced by Wendy Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Stock. The network helps show where Wendy Stock may publish in the future.
Co-authors
The 25 scholars most cited alongside Wendy Stock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 503 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Hit paper breakdown → | 2022 | 1856 |
| 2 | Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia Hit paper breakdown → | 2014 | 1116 |
| 3 | Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia Hit paper breakdown → | 2016 | 1115 |
| 4 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes Hit paper breakdown → | 2016 | 679 |
| 5 | The genomic landscape of hypodiploid acute lymphoblastic leukemia Hit paper breakdown → | 2013 | 556 |
| 6 | 2006 | 489 | |
| 7 | What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Hit paper breakdown → | 2008 | 461 |
| 8 | PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia Hit paper breakdown → | 2019 | 450 |
| 9 | A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Hit paper breakdown → | 2019 | 375 |
| 10 | 2001 | 365 | |
| 11 | High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults Hit paper breakdown → | 2017 | 348 |
| 12 | 2010 | 320 | |
| 13 | Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study Hit paper breakdown → | 2019 | 280 |
| 14 | 2014 | 263 | |
| 15 | Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study Hit paper breakdown → | 2020 | 253 |
| 16 | 2016 | 250 | |
| 17 | 2016 | 236 | |
| 18 | 2015 | 235 | |
| 19 | Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Hit paper breakdown → | 2021 | 227 |
| 20 | 2010 | 221 |
About Wendy Stock
Wendy Stock is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Genetics, Oncology and Pediatrics, Perinatology and Child Health, having authored 503 papers that have together received 22.6k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (222 papers), Acute Myeloid Leukemia Research (201 papers), Chronic Myeloid Leukemia Treatments (104 papers), Chronic Lymphocytic Leukemia Research (74 papers), Hematopoietic Stem Cell Transplantation (62 papers), Childhood Cancer Survivors' Quality of Life (61 papers), CAR-T cell therapy research (41 papers) and Lymphoma Diagnosis and Treatment (41 papers). The work is most often cited by research in Hematology (11.4k citations), Genetics (3.9k citations), Public Health, Environmental and Occupational Health (8.3k citations), Oncology (4.8k citations) and Pediatrics, Perinatology and Child Health (3.1k citations). Wendy Stock has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Richard A. Larson, Daniel DeAngelo, Hagop Kantarjian, Koen van Besien, Anjali S. Advani, Andrew S. Artz, Erik R. Vandendries, Matthias Stelljes, Nicola Gökbuget and Michaela Liedtke. Their work appears in journals such as Blood, Blood Advances, Transplantation and Cellular Therapy, Bone Marrow Transplantation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.